Business
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
Coya previously announced results from an open-label study of COYA 301 in 8 patients with Alzheimer’s disease (AD) that resulted in a statistically
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\n\n Coya previously announced results from an open-label study of COYA 301 in 8 patients with Alzheimer’s disease (AD) that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE).\n\n\n\nCoya to present on additional blood biomarker data for pro- inflammatory cytokines Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) from the recently presented 8 patient investigator-initiated AD study\n\n\n\nIncreased systemic levels of TNF-α, IL-6, and IL-1β have been associated with cognitive decline and may play a role in the pathogenesis and pathophysiology of AD\n\n\n\nCoya also to provide a case report documenting pre- and post-treatment Positron Emission Technology (PET) imaging illustrating the impact of COYA 301 treatment on brain inflammation in one patient that showed cognitive improvement\n\n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance Treg function, including biologics and cell therapies, announced today that it will report new biomarker and brain imaging data from its open-label proof-of-concept clinical study for COYA 301 in patients with Alzheimer’s Disease at the LD Micro Conference:\n\n\nDate: June 7, 2023\n\n\nTime: 11:00am PT\n\n\nWebcast: Register to watch virtually at https://ldinv13.sequireevents.com/\n\n\nFor more information about the conference or to schedule a one-on-one meeting with management contact your conference representative or email [email protected].\n\n\nAbout Coya Therapeutics, Inc.\n\n\nHeadquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restori...